Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Two peptides, pramlintide (37 amino acids), an analog of human amylin, and exenatide, synthetic exendin-4 (39 amino acids), are both in late-stage clinical development as potential new treatments for people with diabetes. Both are potential long-term treatments, and there is the likelihood that some women will become pregnant while using one of these peptide therapies. Therefore, it was important to evaluate the potential for each peptide to cross the placental barrier and thereby result in exposure to the fetus. This was examined using ex vivo perfusions of human placentas. The fetal and maternal side of a cotyledon were cannulated and perfused first with buffer, and then with radioactive antipyrine in order to establish the integrity of the system and the perfusion constants. Either pramlintide or exenatide was then added to each acceptable cotyledon perfusate on the maternal side. Each peptide was evaluated at an initial concentration near the therapeutic plasma concentration and at approximately 10-50 times that concentration in each of the three cotyledons. Maternal and fetal perfusate samples were assayed for peptide concentrations using an immunoassay. The ratio of fetal-to-maternal peptide concentrations during equilibrium perfusion were extremely low (pramlintide ≤ 0.006, exenatide 5 ≤ 0.017). These data demonstrate negligible passage of either peptide across the placental barrier. It is, therefore, likely that maternal use of either peptide during gestation will result in negligible exposure to the fetus.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In human studies, exenatide (GLP1-agonist) showed a fetal-to-maternal peptide concentration ratio of ≤ 0.017 in ex vivo human placental perfusion in a single placenta.”
From Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence (2023) · cites this paper as [34]
In the citing paper
“Similarly, the fetal effects of exenatide, which has a negligible fetal-to-maternal peptide concentration ratio during ex vivo human placental perfusion, are probably due to maternal side effects (34).”
From Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence (2023) · cites this paper as [34]
Citations
Cites
Criteria for Evaluating Perfusion Experiments and Presentation of Results
Challier, J.-C. (1985) · Contributions to gynecology and obstetrics · doi:10.1159/000410667 · Cited by 92
Brandes, J. M., Tavoloni, N., Potter, B. J., Sárközi, L., Shepard, M. D., & Berk, P. D. (1983) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(83)91081-5 · Cited by 73
Placental transfer of cefoperazone and sulbactam in the isolated in vitro perfused human placenta
Fortunato, S. J., Bawdon, R. E., & Baum, M. G. (1988) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(88)80188-1 · Cited by 14
Self-citationInsulin transfer in the isolated human placenta.
Jm, K., & Krohmer, J. S. (1968) · PubMed · Cited by 14
Wn, S., & Wc, B. (1976) · PubMed · Cited by 11
Research works printed but not linked: 2
- Keller JM, 1968, Obstet Gynecol, 32, 77
- Spellacy WN, 1976, Obstet Gynecol, 47, 291
Cited by
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Management of Preexisting Diabetes in Pregnancy: A Review
Alexopoulos, A.-S., Blair, R., & Peters, A. L. (2019) · JAMA · doi:10.1001/jama.2019.4981 · Cited by 174
Muller, D. R. P., Stenvers, D. J., Malekzadeh, A., Holleman, F., Painter, R. C., & Siegelaar, S. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1215356 · Cited by 174
“The only other human study was an ex vivo equilibrium perfusion experiment of human placentas with exenatide that measured a fetal-to-maternal peptide concentration ratio of ≤ 0.017 meaning negligible placental passage (34).”
BackgroundInfluentialThe safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review
Aroda, V. R., & Ratner, R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1202 · Cited by 112
“A study of ex vivo perfusion of human placental tissue by exenatide, however, found negligible passage of the drug across the placenta [49].”
Background
Metadata
- Authors
- Hiles, R. A., Bawdon, R. E., & Petrella, E. M.
- Affiliations
- Amylin Pharmaceuticals, Inc., San Diego, CA, USA; 9373 Towne Centre Drive, San Diego, CA 92121, USA
- The University of Texas Southwestern Medical Center (US)
- Amylin Pharmaceuticals, Inc., San Diego, CA, USA
- Corresponding author
- Hiles, Richard A
- Venue
- Human & Experimental Toxicology
- Publisher
- SAGE Publications
- Published
- 2003-12
- Volume
- 22
- Issue
- 12
- Pages
- 623-628
- ISSN
- 0960-3271 (ISSN-L)
- 1477-0903
- OpenAlex
- W1991138106
- Cited by
- 46
- References
- 5
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 1 · 2023: 4 · 2022: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 2 · 2012: 1
- FWCI
- 2.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Human & Experimental Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- pramlintide, exenatide, exendin-4, amylin analogues, placental transfer, placental barrier, prenatal exposure, diabetes treatment, pregnancy, ex vivo placental perfusion
- MeSH terms
- Exenatide, Amyloid, Catheterization, Drug Evaluation, Preclinical, Female, Humans, Hypoglycemic Agents, Insulin, Maternal-Fetal Exchange, Metabolic Clearance Rate, Peptides, Perfusion, Placenta, Pregnancy, Venoms, Placental Circulation, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). https://app.cochat.ai/papers/10.1191/0960327103ht402oa
- The paper
- Hiles, R. A., Bawdon, R. E., & Petrella, E. M. (2003). Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). Human & Experimental Toxicology. https://doi.org/10.1191/0960327103ht402oa
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.